Mpox (monkeypox) vaccine Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix Mpox vaccine safety surveillance conducted by AusVaxSafety was completed on 17 April 2023. Data on this page will no longer be updated. Safety data collected from more than 15,000 JYNNEOS mpox vaccine recipients identified no safety issues in either administration method, intradermal and subcutaneous.The Therapeutic Goods Administration (TGA) continues to monitor the safety of mpox vaccines in Australia. Mpox vaccine safety dataClick on the tiles below to view subcutaneous and intradermal mpox vaccine safety data. Intradermal JYNNEOS mpox (monkeypox) vaccine View the latest intradermal JYNNEOS mpox vaccine safety data here Subcutaneous JYNNEOS mpox (monkeypox) vaccine View the latest subcutaneous JYNNEOS mpox vaccine safety data here Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix News & events All news & events 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations 18 May 2025 | News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination 31 March 2025 | News AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines